Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan · Delayed Price · Currency is JPY 6,885.00
+38.00 (0.55%)
Aug 19, 2026, 3:30 PM JST
Chugai Pharmaceutical Ratios and Metrics
Market cap in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,265,389 | 13,565,544 | 11,516,953 | 8,789,053 | 5,540,406 | 6,141,311 | |
Market Cap Growth | 9.65% | 17.79% | 31.04% | 58.64% | -9.79% | -32.11% |
Enterprise Value | 10,302,816 | 12,683,097 | 10,671,635 | 8,170,288 | 4,995,111 | 5,744,662 |
Last Close Price | 6847.00 | 8169.82 | 6703.26 | 5038.50 | 3122.66 | 3386.32 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.91 | 31.26 | 29.74 | 27.00 | 14.80 | 20.27 |
Forward PE | 20.58 | 29.02 | 29.26 | 26.55 | 18.61 | 22.33 |
PS Ratio | 8.39 | 10.78 | 9.84 | 7.91 | 4.40 | 6.14 |
PB Ratio | 5.56 | 6.70 | 6.06 | 5.41 | 3.89 | 5.17 |
P/TBV Ratio | 5.72 | 6.88 | 6.11 | 5.47 | 3.96 | 5.27 |
P/FCF Ratio | 28.12 | 43.76 | 29.00 | 26.01 | 30.53 | 28.74 |
P/OCF Ratio | 25.07 | 35.12 | 25.73 | 21.44 | 22.70 | 21.96 |
PEG Ratio | 1.88 | 3.16 | 4.20 | 23.02 | 4.08 | 2.37 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.67 | 10.08 | 9.12 | 7.35 | 3.97 | 5.75 |
EV/EBITDA Ratio | 15.39 | 20.09 | 18.60 | 17.35 | 8.85 | 12.69 |
EV/EBIT Ratio | 16.19 | 21.18 | 19.69 | 18.60 | 9.37 | 13.62 |
EV/FCF Ratio | 25.71 | 40.91 | 26.87 | 24.17 | 27.52 | 26.89 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | - | 0.04 | 0.02 | 0.03 | 0.02 | 0.04 |
Debt / FCF Ratio | - | 0.08 | 0.03 | 0.04 | 0.08 | 0.08 |
Net Debt / Equity Ratio | -0.47 | -0.47 | -0.52 | -0.45 | -0.34 | -0.38 |
Net Debt / EBITDA Ratio | -1.45 | -1.51 | -1.72 | -1.54 | -0.87 | -1.01 |
Net Debt / FCF Ratio | -2.40 | -3.08 | -2.48 | -2.15 | -2.69 | -2.13 |
Asset Turnover | 0.57 | 0.54 | 0.56 | 0.59 | 0.74 | 0.72 |
Inventory Turnover | 1.39 | 1.41 | 1.32 | 1.46 | 1.90 | 1.72 |
Quick Ratio | 3.43 | 3.46 | 4.59 | 3.68 | 2.40 | 2.53 |
Current Ratio | 4.35 | 4.24 | 5.53 | 4.74 | 3.15 | 3.25 |
Return on Equity (ROE) | 23.49% | 22.10% | 21.96% | 21.34% | 28.67% | 27.95% |
Return on Assets (ROA) | 16.83% | 16.00% | 16.36% | 14.44% | 19.56% | 19.01% |
Return on Invested Capital (ROIC) | 43.14% | 43.74% | 42.57% | 35.09% | 45.09% | 45.33% |
Return on Capital Employed (ROCE) | 30.90% | 29.10% | 28.30% | 26.70% | 36.90% | 34.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.18% | 3.20% | 3.36% | 3.70% | 6.76% | 4.93% |
FCF Yield | 3.56% | 2.28% | 3.45% | 3.84% | 3.28% | 3.48% |
Dividend Yield | 1.92% | 1.49% | 1.46% | 1.59% | 2.50% | 2.24% |
Payout Ratio | 94.94% | 68.99% | 34.40% | 40.43% | 36.91% | 32.56% |
Buyback Yield / Dilution | -0.00% | -0.01% | -0.01% | -0.01% | -0.01% | -0.01% |
Total Shareholder Return | 1.92% | 1.49% | 1.45% | 1.58% | 2.49% | 2.23% |